Why This Matters
Cardiovascular disease remains the leading cause of death in the United States. But embedded within that grim statistic is one of modern medicine's most underappreciated success stories: deaths from ischemic heart disease, the category that includes heart attacks and the arterial blockages that cause them, have fallen dramatically over the past generation.
A new study published in JAMA Cardiology on July 15, 2026, using data from the Global Burden of Disease Study 2023, quantifies exactly how much of that decline is attributable to modifiable risk factors, meaning behaviors and conditions that people and clinicians can actually change. The answer is striking: most of the improvement came not from new surgical procedures or novel pharmaceuticals, but from population-level changes in smoking rates, blood pressure control, cholesterol management, and diet.
The finding matters not as reassurance but as a roadmap. If modifiable risk factors drove most of the gains, they are also where the work must continue — particularly because two of those same risk factors, high body mass index and elevated fasting blood sugar, are now trending in the wrong direction.
What We Know So Far
Researchers from the Global Burden of Disease 2023 US IHD Collaborators, including Cathleen Benziger, MD, at the American College of Cardiology, analyzed data from the GBD 2023 study covering estimated ischemic heart disease death rates and risk factor exposure for U.S. study participants between 1990 and 2023. The analysis is published in JAMA Cardiology (DOI: 10.1001/jamacardio.2026.1847, published online July 15, 2026).
Overall, total IHD deaths in the United States declined by 59% from 1990 to 2023, according to Medical News Today's July 21 reporting on the study. Within that broad decline, the improvements were driven primarily by changes in population-level modifiable risk factors rather than by any single therapeutic intervention.
Among the specific findings:
Smoking showed the greatest reduction in attributable mortality burden over the study period. The burden of IHD deaths attributable to smoking declined by approximately 33% since 1990. Air pollution (particulate matter) showed an even larger reduction, with attributable IHD deaths from particulate matter pollution declining by approximately 75%.
At the same time, two risk factors are moving in the opposite direction. Deaths attributable to high body mass index increased over the study period, and deaths attributable to high fasting plasma glucose (elevated blood sugar, including in pre-diabetic and diabetic ranges) also increased. The ACC summary noted that the pace of improvement has slowed in recent years despite the overall long-term gains.
Where the Risk Is Highest — And Where Progress Has Stalled
The GBD analysis also examined state-level variation, finding significant geographic disparities. States in the Southeast and Central Plains have consistently higher rates of IHD mortality attributable to modifiable risk factors, reflecting both higher rates of risk factor prevalence (smoking, hypertension, diabetes, and obesity) and lower rates of cardiovascular risk factor control.
The convergence of rising BMI-related and blood sugar-related IHD mortality with regional disparities in prevention means that the population gains of the past 33 years are not shared equally. People in low-income communities, rural areas, and states with lower rates of preventive care access face a different risk profile than the national average suggests.
What Doctors and Experts Say
The American College of Cardiology's summary of the study highlighted the clear practical implication: the modifiable risk factors that drove the decline are the same ones that must continue to be addressed to sustain and extend the improvement.
High systolic blood pressure remains the leading single modifiable risk factor for IHD mortality in the United States, according to GBD 2023 data. Diet quality and LDL cholesterol are next. Together, blood pressure control, dietary improvement, LDL reduction, and continued declines in smoking account for the majority of the mortality reduction achieved since 1990.
The significance of the BMI and blood sugar findings should not be understated. The GBD analysis suggests that the gains from smoking reduction and air pollution improvement are being partially offset by the growing cardiovascular toll of obesity and type 2 diabetes. That is a public health warning, not just a research finding.
What the Evidence Shows and What It Does Not
The GBD 2023 analysis uses modeled estimates from multiple data sources, including death certificates, health surveys, and disease surveillance systems. The attribution of deaths to specific risk factors uses counterfactual analysis, asking how many deaths would have occurred if the risk factor were at its theoretically optimal level. These methods are well-established in epidemiology but involve modeling assumptions that produce uncertainty ranges around each estimate.
The study quantifies attributable mortality burden and does not establish causal mechanisms for individual patients. The relative contributions of lifestyle changes versus pharmaceutical interventions (statins, antihypertensives, antiplatelet drugs) to the IHD mortality decline are not cleanly separable in a population-level analysis.
MedicalDaily Evidence Check
- Study type: Systematic analysis of Global Burden of Disease Study 2023 data
- Source: JAMA Cardiology, July 15, 2026 (DOI: 10.1001/jamacardio.2026.1847); ACC summary July 20, 2026
- Time period: 1990 to 2023 (33 years)
- What it found: U.S. ischemic heart disease deaths fell 59% overall; smoking and particulate matter pollution showed the largest reductions in attributable burden; deaths attributed to high BMI and high fasting plasma glucose increased
- What it does not prove: Direct causal mechanisms for individual patients; precise separation of lifestyle versus pharmaceutical contributions
-
What readers should know: Blood pressure control, smoking cessation, LDL management, and diet quality remain the highest-leverage modifiable risk factors; the rising burden from obesity and blood sugar represents a threat to continued progress
Who Faces the Greatest Risk?
Based on the GBD 2023 analysis and related cardiovascular epidemiology:
- Adults with uncontrolled hypertension, which remains the most common modifiable risk factor for IHD death
- People who smoke or who have recently quit, given the large ongoing contribution of smoking to IHD mortality
- Adults with type 2 diabetes or pre-diabetes, given the documented rise in blood sugar-attributable IHD deaths
- Adults with obesity, particularly those with abdominal obesity and metabolic syndrome
- People in rural areas and the Southeastern United States, where both risk factor prevalence and treatment gaps are highest
-
Men, who consistently face higher IHD mortality rates than women across the study period
Symptoms and Warning Signs to Watch For
Ischemic heart disease often develops silently for years before causing symptoms. Warning signs that require prompt medical evaluation include:
- Chest pain, pressure, tightness, or squeezing, especially with exertion
- Shortness of breath, with or without chest discomfort
- Pain or discomfort radiating to the left arm, neck, jaw, back, or upper abdomen
- Sudden cold sweats, nausea, or lightheadedness
- Unexplained fatigue, particularly in women who may present with atypical symptoms
These symptoms during or after physical activity are particularly significant. Chest pain at rest or that does not resolve within minutes requires emergency medical evaluation.
What You Can Do Now
- Know your numbers. Blood pressure, LDL cholesterol, fasting blood sugar, and BMI are the four most actionable cardiovascular risk measures. Ask your clinician to review all four at your next appointment if you have not had them checked in the past year.
- If you smoke, the single most impactful cardiovascular health action you can take is quitting. The CDC's Quitline at 1-800-QUIT-NOW provides free support.
- Work with your physician to optimize blood pressure and cholesterol control if either is above target. Medication adherence is as important as the initial prescription.
- Reduce processed food and added sugar intake, which are directly associated with both elevated blood sugar and LDL cholesterol.
-
Aim for at least 150 minutes of moderate aerobic activity per week, as physical inactivity is among the risk factors documented in the GBD study.
Cost and Access: What Patients Should Know
Blood pressure medications, statins, and aspirin regimens, the core pharmaceutical contributors to the IHD mortality decline, are among the most widely available and low-cost generic medications in American pharmacies. Many are available at under $10 per month through major pharmacy chains. Medicare Part D covers all major cardiovascular preventive medications, and most private insurance plans include them as preferred generic drugs.
For uninsured adults, federally qualified health centers provide cardiovascular risk screening and preventive medication at sliding-scale cost. The American Heart Association's blood pressure information center includes guidance on finding affordable care.
What Happens Next
The GBD 2023 data, which covers through 2023, is the most complete long-term dataset available on U.S. cardiovascular mortality trends. The next GBD update will incorporate 2024 and 2025 data, which will begin to capture any impact of GLP-1 drug use on obesity and diabetes-related cardiovascular outcomes. Researchers will be watching whether the rising BMI and blood sugar burden begins to reverse as GLP-1 medications reach broader populations with Medicare and Medicaid coverage.
The Bottom Line
A 33-year analysis confirms what cardiovascular medicine has long believed but rarely quantified directly: the dramatic decline in U.S. heart attack deaths was driven primarily by population-level improvements in smoking, blood pressure, cholesterol, and diet. That is genuinely good news. The equally important finding is that high BMI and elevated blood sugar are moving in the opposite direction, partially eroding those gains. Sustaining the progress of the past generation requires the same tools that produced it: controlling blood pressure, eliminating smoking, managing cholesterol, and addressing obesity and diabetes with the clinical seriousness they deserve.
